Lupin has successfully completed GMP inspection as well as a PAI inspection (Prior Approval Inspection) carried out by the United States Food and Drug Administration (USFDA) at its Pithampur manufacturing facility - Unit 1 without any observations. The inspection which started on July 24, 2017 concluded on July 28, 2017.
Earlier, USFDA had successfully completed PAI at company's Goa manufacturing facility without any observations. The inspection which started on July 17 concluded on July 21, 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.